Current Pharmacological Trends on Myricetin
Autor: | Mohd Aftab Siddiqui, Afroz Ahmad, Mohd Ajmal, Mohd Muazzam Khan, Azizur Rahaman, Rabiya Ahsan, Gudiya Gupta, Arshad, Mohammad Khushtar |
---|---|
Rok vydání: | 2020 |
Předmět: |
Antioxidant
Heart Diseases medicine.medical_treatment Pharmacology Polygonaceae 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Alzheimer Disease Dimethyl formamide Biological property Neoplasms Drug Discovery medicine Diabetes Mellitus Animals Humans 030304 developmental biology Flavonoids Inflammation 0303 health sciences Ethanol Epilepsy Plants Medicinal biology Dimethyl sulfoxide Liver Diseases Metabolic disorder General Medicine medicine.disease biology.organism_classification Disease Models Animal chemistry Solubility 030220 oncology & carcinogenesis Osteoporosis Myricetin |
Zdroj: | Drug research. 70(10) |
ISSN: | 2194-9387 |
Popis: | Myricetin is a member of the group of flavonoids called flavonols. Myricetin is obtained from various fruit, vegetables, tea, berries and red wine. Myricetin is characterized by the pysrogallol B-ring, and the more hydroxylated structure is known to be capable for its increased biological properties compared with other flavonols. Myricetin is produced by the Myricaceae, Anacardiaceae, Polygonaceae, Pinaceae and Primulacea families. It is soluble in organic solvent such as ethanol, DMSO (dimethyl sulfoxide), and dimethyl formamide (DMF). It is sparingly soluble in aqueous buffers. Myricetin shows its various pharmacological activities including antioxidant, anti-amyloidogenic, antibacterial, antiviral, antidiabetic, anticancer, anti-inflammatory, anti-epileptic and anti-ulcer. This review article focuses on pharmacological effects of Myricetin on different diseases such as osteoporotic disorder, anti-inflammatory disorder, alzheimer’s disease, anti-epileptic, cancer, cardiac disorder, diabetic metabolic disorder, hepatoprotective disorder and gastro protective disorder. |
Databáze: | OpenAIRE |
Externí odkaz: |